Eledon Pharmaceuticals, Inc. announced the publication of a study evaluating tegoprubart as an immunomodulatory monotherapy in nonhuman primate kidney and islet allotransplants. The study, entitled ?The anti-CD40L monoclonal antibody AT-1501 promotes islet and kidney allograft survival and function in nonhuman primates?, was published in the August 30, 2023, issue of Science Translational Medicine. Results from the study showed that treatment with tegoprubart as a monotherapy promoted long-term kidney and islet allograft survival and function in nonhuman primates, indicating its potential as an immunomodulatory agent for organ transplantation.

In the study, tegoprubart did not bind to Fc receptors or promote platelet aggregation in vivo, thereby minimizing the risk of thromboembolic complications, while also retaining a high binding affinity to CD40L. Additionally, phenotypes of both CD4+ and CD8+ cells remained similar throughout the study. Eledon recently initiated the BESTOW study, a phase 2 study enrolling approximately 120 participants undergoing kidney transplantation to assess the efficacy and safety of tegoprubart compared to the standard of care (tacrolimus).

The Company previously reported clinical data at the World Congress of Nephrology from its ongoing Phase 1b study evaluating tegoprubart in kidney transplantation, demonstrating no incidence of acute rejection and strong graft function in the first three enrolled participants. Eledon expects to report updated clinical data from the Phase 1b study at the American Society of Nephrology (ASN) Kidney Week Annual Meeting in November 2023.